Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2008

01-09-2008 | Original Paper

Expression and clinical significance of NET-1 and PCNA in hepatocellular carcinoma

Authors: Shi-Qiang Shen, Kun Li, Neng Zhu, Akimasa Nakao

Published in: Medical Oncology | Issue 3/2008

Login to get access

Abstract

Objective Objective of this study was to detect the expression of neuroepithelial transforming gene-1 (NET-1) and proliferating cell nuclear antigen (PCNA) in hepatocellular carcinoma (HCC) and adjacent tissues, and to investigate the relation of the expression of NET-1 in HCC tissue with cancer proliferation, metastasis and clinic stages. Methods The expression of NET-1 mRNA was detected by reverse transcription-polymerase chain reaction method in 34 human HCC tissues, and it was matched with 34 paracarcinoma tissues. The expression of PCNA in HCC was analyzed by immunohistochemistry. Meanwhile, the relation of the expression with clinic pathological features of HCC was evaluated, and the correlation between the expression of NET-1 and PCNA in HCC was investigated. Results Expression of NET-1 was significantly higher in HCC than that in matched paracarcinoma tissues. The expression of NET-1 was significantly higher in TMN III–IV HCC tissues when compared with TMN I–II HCC tissues (P < 0.05). The expression level of NET-1 in HCC tissues was related to intrahepatic metastasis and portal vein infiltration. The expression of NET-1 in HCC tissues was positively correlated with PCNA. Conclusions The expression of NET-1 may relate to proliferation, metastasis and clinic stages of HCC. The expression of NET-1 in HCC tissues may positively correlate to the TMN stages.
Literature
1.
Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127:S87–S96.PubMedCrossRef
2.
Symons M, Rusk N. Control of vesicular trafficking by Rho GTPases. Curr Biol 2003;13:409–18.CrossRef
3.
Alberts AS, Treisman R. Activation of RhoA and SAPK/JNK signalling pathways by the RhoA-specific exchange factor mNET1. EMBO J 1998;17:4075–85.PubMedCrossRef
4.
Wollscheid V, Kuhne-Heid R, Stein I, et al. Identification of a new proliferation-associated protein net-1/c4-8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2002;99(6):771–5.PubMedCrossRef
5.
Leyden J, Murray D, Moss A, et al. NET-1 and Myeov: computationally identified mediators of gastric cancer. Br J Cancer 2006;94(8):1204–12.PubMedCrossRef
6.
Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007;13(1):74–81.PubMed
7.
Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006;12(47):7604–12.PubMed
8.
Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006;12(47):7561–7.PubMed
9.
Park Y, Chae KJ, Kim YB, et al. Apoptosis and proliferation in hepatocarcinogenesis related to cirrhoisis. Cancer 2001;92(11):2733–8.PubMedCrossRef
10.
Pizem J, Marolt VF, Luzar B, et al. Proliferative and apoptotic activity in hepatocellular carcinoma and surrounding non-neoplastic liver tissue. Pflugers Arch 2001;442(6 Suppl 1):174–6.CrossRef
11.
Zeng WJ, Liu GY, Xu J, Zhou XD, Zhang YE, Zhang N. Pathological characteristics, PCNA labeling index and DNA index in prognostic eveluation of patients with oderately differentiated hepatocellular carcinoma. World J Gastroenterol 2002;8:1040–4.PubMed
12.
Kong XB, Liang LJ, Huang JF. A Study of correlation between apoptosis,expression of p21 protein and PCNA and the clinical prognosis in hepatocellular carcinoma. Aizheng J 1999;18:426–9.
13.
Shen LJ, Zhang HX, Zhang ZJ, et al. Detection of HBV, PCNA and GST-pi in hepatocelluar carcinoma and chronic liver diseases. World J Gastroenterol 2003;9(3):459–62.PubMed
14.
Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005;6:167–80.PubMedCrossRef
15.
16.
17.
18.
Yauch RL, Hemler ME. Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase. Biochem J 2000;351:629–37.PubMedCrossRef
19.
Serru V, Dessen P, Boucheix C, Rubinstein E. Sequence and expression of seven new tetraspans. Biochim Biophys Acta 2000;1478:159–63.PubMed
20.
Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997;11(6):428–42.PubMed
21.
Serru V, Le Naour F, Billard M, et al. Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem J 1999;340:103–11.PubMedCrossRef
Metadata
Title
Expression and clinical significance of NET-1 and PCNA in hepatocellular carcinoma
Authors
Shi-Qiang Shen
Kun Li
Neng Zhu
Akimasa Nakao
Publication date
01-09-2008
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 3/2008
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9042-6

Other articles of this Issue 3/2008

Medical Oncology 3/2008 Go to the issue

Original Paper

Functional characterization of the HOXB13 promoter region

REVIEW

Understanding and management of male breast cancer: a critical review

Original Paper

The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma

Original Paper

Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases

Original Paper

Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study

CASE REPORT

Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits